Cargando…
First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab
Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488311/ https://www.ncbi.nlm.nih.gov/pubmed/28695019 http://dx.doi.org/10.1155/2017/6458636 |